Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.
Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin (Yondelis) in uterine and soft tissue leiomyosarcoma.
The secondary end point of the LMS-02 study was to evaluate overall survival (OS) after a medium follow-up of 7 years, says Pautier. The updated results were encouraging, reflecting a median OS of about 34.4 months in the entire population. The results were less impressive in patients with uterine leiomyosarcoma with a median OS of 27.5 months, adds Pautier. However, the median OS was 38.7 months in patients with soft tissue leiomyosarcoma.
Additionally, two phase 3 studies that were done in the first-line setting in the same patient population showed a median OS ranging from 22 to 29 months with doxorubicin alone or doxorubicin in combination with another agent in patients with soft tissue sarcoma, adds Pautier.
Now, a phase 3 study (NCT02997358) is comparing doxorubicin alone versus the combination of doxorubicin and trabectedin followed by trabectedin in patients who do not progress after 6 cycles of treatment. The results from this research are pending and will be read out soon, concludes Pautier.